Programmable Biosynthesis of Plant‐Derived 4′‐Deoxyflavone Glycosides by an Unconventional Yeast Consortium
Small Methods · 2024-08 · 8 (8)
DOI: 10.1002/smtd.202301371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small Methods, online erschienen am 13.02.2024. Verfasst von Yijia Kang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China. Hauptthemen laut MEDLINE: Glycosides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key Research and Development Program of China, 111 project, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism (Shanghai Municipal Education Commission.
Abstract (Originalsprache)
Previous data established 4′‐deoxyflavone glycosides (4′‐DFGs) as important pharmaceutical components in the roots of rare medical plants like Scutellaria baicalensis Georgi. Extracting these compounds from plants involves land occupation and is environmentally unfriendly. Therefore, a modular (“plug‐and‐play”) yeast‐consortium platform is developed to synthesize diverse 4′‐DFGs de novo. By codon‐optimizing glycosyltransferase genes from different organisms for Pichia pastoris , six site‐specific glycosylation chassis are generated to be capable of biosynthesizing 18 different 4′‐DFGs. Cellular factories showed increased 4′‐DFG production (up to 18.6‐fold) due to strengthened synthesis of UDP‐sugar precursors and blocked hydrolysis of endogenous glycosides. Co‐culturing upstream flavone‐synthesis‐module cells with downstream glycoside‐transformation‐module cells alleviated the toxicity of 4′‐deoxyflavones and enabled high‐level de novo synthesis of 4′‐DFGs. Baicalin is produced at the highest level (1290.0 mg L −1 ) in a bioreactor by controlling the consortium through carbon‐source shifting. These results provide a valuable reference for biosynthesizing plant‐derived 4′‐DFGs and other glycosides with potential therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
- Shanghai Key Laboratory of Plant Functional Genomics and Resources, Shanghai Chenshan Botanical Garden, Shanghai, 201602, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- China Resources Biopharmaceutical Co., Ltd., Shenzhen, 518132, China.
ORCID-Profile: Menghao Cai
Förderung
- National Key Research and Development Program of China
- 111 project
- Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism (Shanghai Municipal Education Commission
- Higher Education Discipline Innovation Project
Zitieren
APA
Kang, Y., Qian, Z., Yu, H., Lu, J., Zhao, Q., Qiao, X., Ye, M., Zhou, X., & Cai, M. (2024). Programmable Biosynthesis of Plant‐Derived 4′‐Deoxyflavone Glycosides by an Unconventional Yeast Consortium. Small Methods, 8(8). https://doi.org/10.1002/smtd.202301371
Vancouver
Kang Y, Qian Z, Yu H, Lu J, Zhao Q, Qiao X, et al. Programmable Biosynthesis of Plant‐Derived 4′‐Deoxyflavone Glycosides by an Unconventional Yeast Consortium. Small Methods. 2024;8(8). doi:10.1002/smtd.202301371
BibTeX
@article{Kang2024,
author = {Kang, Yijia and Qian, Zhilan and Yu, Haishuang and Lu, Jian and Zhao, Qing and Qiao, Xue and Ye, Min and Zhou, Xiangshan and Cai, Menghao},
title = {Programmable Biosynthesis of Plant‐Derived 4′‐Deoxyflavone Glycosides by an Unconventional Yeast Consortium},
journal = {Small Methods},
year = {2024},
volume = {8},
number = {8},
doi = {10.1002/smtd.202301371}
}
EUVIMED